hemophilia A
FDA Approves Qfitlia for Hemophilia A or B
The FDA approved Qfitlia for adults and children 12 years of age and older with hemophilia A or B, with or without ...
APRIL 7, 2025
Altuviiio Highly Effective Against Bleeding in Children With Severe Hemophilia A
The phase 3 XTEND-Kids study evaluating antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, ...
JUNE 26, 2023
BioCareSD Adds Altuviiio to Its Specialty Therapeutics Portfolio
BioCareSD announced that Altuviiio is now available through its network.
APRIL 13, 2023
FDA Expands Indication for Hemlibra to Include Non-Factor VIII Inhibitors
The FDA has expanded the indication for emicizumab-kxwh injection (Hemlibra, Genentech) to include adults and ...
OCTOBER 4, 2018
New Drug for Hemophilia A Approved by FDA
The FDA has approved a new prophylactic treatment for adults and adolescents with hemophilia A.
SEPTEMBER 4, 2018
FDA Approves First Hemophilia A With Inhibitors Treatment in 20 Years
Genentech's Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
NOVEMBER 17, 2017
FDA Gives Designations to Hemophilia Gene Therapies
Shire's SHP654 gets orphan drug designation and investigational new drug (IND) status; breakthrough therapy ...
OCTOBER 27, 2017
New Indication Granted for Adynovate
Adynovate can now be used for children younger than 12 years of age.
DECEMBER 27, 2016
Researchers Target Inhibitors in Hemophilia A
New multicenter trial to focus on individualized immune tolerance induction (ITI) therapy.
NOVEMBER 18, 2016
